Email Alert RSS
Volume 11 Issue 4
Jul.  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2020  >  11(4): 459-464
Hui TANG, Jian-feng ZHOU, Chun-mei BAI. Clinical Progress of Immune Checkpoint Inhibitors in the Elderly[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 459-464. doi: 10.3969/j.issn.1674-9081.2020.04.018
Citation: Hui TANG, Jian-feng ZHOU, Chun-mei BAI. Clinical Progress of Immune Checkpoint Inhibitors in the Elderly[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 459-464. doi: 10.3969/j.issn.1674-9081.2020.04.018
shu

Clinical Progress of Immune Checkpoint Inhibitors in the Elderly

doi: 10.3969/j.issn.1674-9081.2020.04.018

  • Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: ZHOU Jian-feng  Tel: 86-10-69158764, E-mail:ZhouJF@pumch.cn
  • Received Date: 2019-11-22
  • Publish Date: 2020-07-30
    Abstract
  • The use of immune checkpoint inhibitors (ICIs) is a revolutionary breakthrough in cancer treatment, which has changed the treatment modality for many types of tumors. The elderly account for the majority of cancer cases and deaths. There are some factors that may affect the treatment of ICIs in aging patients, such as immunosenescence, high incidence of autoimmune diseases and infectious diseases, and difference of tumor mutational burden from young patients. In most clinical trials of ICIs, aging patients did not account for the due proportion of the participants. Results of subgroup analysis and meta-analysis showed that age had little effect on the efficacy of ICIs and immune-related adverse events. Clinicians can refer to the relevant trial data and administer ICIs in elderly cancer patients with good physical condition to accumulate more real-world data.
    • FullText(HTML)
  • loading
    • References(63)
  • [1] Kennedy LC, Bhatia S, Thompson JA, et al. Preexisting Autoimmune Disease:Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors[J]. J Natl Compr Canc Netw, 2019, 17:750-757. doi:  10.6004/jnccn.2019.7310
    [2] Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors:Review of the literature[J]. Eur J Cancer, 2017, 73:1-8. doi:  10.1016/j.ejca.2016.12.001
    [3] SEER Cancer Statistics Review(CSR)1975-2017[EB/OL]. https.//seer.cancer.gov/csr/1975_2017/.
    [4] Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69:363-385. doi:  10.3322/caac.21565
    [5] Repetto L, Audisio RA. Elderly patients have become the leading drug consumers:it's high time to properly evaluate new drugs within the real targeted population[J]. J Clin Oncol, 2006, 24:e62-e63. doi:  10.1200/JCO.2006.09.3039
    [6] Singh H, Beaver JA, Kim G, et al. Enrollment of older adults on oncology trials:An FDA perspective[J]. J Geriatr Oncol, 2017, 8:149-150. doi:  10.1016/j.jgo.2016.11.001
    [7] Daste A, Domblides C, Gross-Goupil M, et al. Immune checkpoint inhibitors and elderly people:A review[J]. Eur J Cancer, 2017, 82:155-166. doi:  10.1016/j.ejca.2017.05.044
    [8] Kirschner K, Chandra T, Kiselev V, et al. Proliferation Drives Aging-Related Functional Decline in a Subpopulation of the Hematopoietic Stem Cell Compartment[J]. Cell Rep, 2017, 19:1503-1511. doi:  10.1016/j.celrep.2017.04.074
    [9] Della Bella S, Bierti L, Presicce P, et al. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly[J]. Clin Immunol, 2007, 122:220-228. doi:  10.1016/j.clim.2006.09.012
    [10] Pence BD, Yarbro JR. Aging impairs mitochondrial respira-tory capacity in classical monocytes[J]. Exp Gerontol, 2018, 108:112-117. doi:  10.1016/j.exger.2018.04.008
    [11] van Duin D, Allore HG, Mohanty S, et al. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults[J]. J Infect Dis, 2007, 195:1590-1597. doi:  10.1086/516788
    [12] Bottazzi B, Riboli E, Mantovani A. Aging, inflammation and cancer[J]. Semin Immunol, 2018, 40:74-82. doi:  10.1016/j.smim.2018.10.011
    [13] Agrawal A, Gupta S. Impact of aging on dendritic cell functions in humans[J]. Ageing Res Rev, 2011, 10:336-345. doi:  10.1016/j.arr.2010.06.004
    [14] Cura Daball P, Ventura Ferreira MS, Ammann S, et al. CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome[J]. Immunol Cell Biol, 2018, 96:1060-1071. doi:  10.1111/imcb.12169
    [15] Zelle-Rieser C, Thangavadivel S, Biedermann R, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site[J]. J Hematol Oncol, 2016, 9:116. doi:  10.1186/s13045-016-0345-3
    [16] Moreira A, Gross S, Kirchberger MC, et al. Senescence markers:Predictive for response to checkpoint inhibitors[J]. Int J Cancer, 2019, 144:1147-1150. doi:  10.1002/ijc.31763
    [17] Aspinall R, Carroll J, Jiang S. Age-related changes in the absolute number of CD95 positive cells in T cell subsets in the blood[J]. Exp Gerontol, 1998, 33:581-591. doi:  10.1016/S0531-5565(98)00035-7
    [18] Cicin-Sain L, Smyk-Pearson S, Currier N, et al. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates[J]. J Immunol, 2010, 184:6739-6745. doi:  10.4049/jimmunol.0904193
    [19] Effros RB, Boucher N, Porter V, et al. Decline in CD28+ T cells in centenarians and in long-term T cell cultures:a possible cause for both in vivo and in vitro immunosenescence[J]. Exp Gerontol, 1994, 29:601-609. doi:  10.1016/0531-5565(94)90073-6
    [20] Bulati M, Caruso C, Colonna-Romano G. From lymphopoiesis to plasma cells differentiation, the age-related modifications of B cell compartment are influenced by "inflamm-ageing"[J]. Ageing Res Rev, 2017, 36:125-136. doi:  10.1016/j.arr.2017.04.001
    [21] Pawelec G. Does patient age influence anti-cancer imm-unity?[J]. Semin Immunopathol, 2019, 41:125-131. doi:  10.1007/s00281-018-0697-6
    [22] Jagger A, Shimojima Y, Goronzy JJ, et al. Regulatory T cells and the immune aging process:a mini-review[J]. Gerontology, 2014, 60:130-137. doi:  10.1159/000355303
    [23] Flores RR, Clauson CL, Cho J, et al. Expansion of myeloid-derived suppressor cells with aging in the bone marrow of mice through a NF-κB-dependent mechanism[J]. Aging Cell, 2017, 16:480-487. doi:  10.1111/acel.12571
    [24] Rosenkranz D, Weyer S, Tolosa E, et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration[J]. J Neuroimmunol, 2007, 188:117-127. doi:  10.1016/j.jneuroim.2007.05.011
    [25] Coppé JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype:the dark side of tumor suppression[J]. Annu Rev Pathol, 2010, 5:99-118. doi:  10.1146/annurev-pathol-121808-102144
    [26] Watad A, Bragazzi NL, Adawi M, et al. Autoimmunity in the Elderly:Insights from Basic Science and Clinics-A Mini-Review[J]. Gerontology, 2017, 63:515-523. doi:  10.1159/000478012
    [27] Khan SA, Pruitt SL, Xuan L, et al. Prevalence of Autoimmune Disease Among Patients With Lung Cancer:Implications for Immunotherapy Treatment Options[J]. JAMA Oncol, 2016, 2:1507-1508. doi:  10.1001/jamaoncol.2016.2238
    [28] Toi Y, Sugawara S, Sugisaka J, et al. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer[J]. JAMA Oncol, 2019, 5:376-383. doi:  10.1001/jamaoncol.2018.5860
    [29] Yoneshima Y, Tanaka K, Shiraishi Y, et al. Safety and Efficacy of PD-1 Inhibitors in Non-Small Cell Lung Cancer Patients Positive for Antinuclear Antibodies[J]. Lung Cancer, 2019, 130:5-9. doi:  10.1016/j.lungcan.2019.01.014
    [30] de Moel EC, Rozeman EA, Kapiteijn EH, et al. Autoantibody development under treatment with immune-checkpoint inhibitors[J]. Cancer Immunol Res, 2019, 7:6-11. doi:  10.1158/2326-6066.CIR-18-0245
    [31] Scott SC, Pennell NA. Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab[J]. J Thorac Oncol, 2018, 13:1771-1775. doi:  10.1016/j.jtho.2018.06.004
    [32] Arbour KC, Mezquita L, Long N, et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2018, 36:2872-2878. doi:  10.1200/JCO.2018.79.0006
    [33] Fucà G, Galli G, Poggi M, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors[J]. ESMO Open, 2019, 4:e000457. doi:  10.1136/esmoopen-2018-000457
    [34] Ricciuti B, Dahlberg SE, Adeni A, et al. Immune Check-point Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications[J]. J Clin Oncol, 2019, 37:1927-1934. doi:  10.1200/JCO.19.00189
    [35] Francino MP. Antibiotics and the Human Gut Microbiome:Dysbioses and Accumulation of Resistances[J]. Front Microbiol, 2016, 6:1543.
    [36] Pinato DJ, Gramenitskaya D, Altmann DM, et al. Antibiotic therapy and outcome from immune-checkpoint inhibitors[J]. J Immunother Cancer, 2019, 7:287. doi:  10.1186/s40425-019-0775-x
    [37] Huang XZ, Gao P, Song YX, et al. Antibiotic Use and the Efficacy of Immune Checkpoint Inhibitors in Cancer Patients:A Pooled Analysis of 2740 Cancer Patients[J]. Oncoimmunology, 2019, 8:e1665973.
    [38] Pinato DJ, Howlett S, Ottaviani D, et al. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer[J]. JAMA Oncol, 2019, 5:1774-1778. doi:  10.1001/jamaoncol.2019.2785
    [39] Podolskiy DI, Lobanov AV, Kryukov GV, et al. Analysis of cancer genomes reveals basic features of human aging and its role in cancer development[J]. Nat Commun, 2016, 7:12157. doi:  10.1038/ncomms12157
    [40] Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden[J]. Genome Med, 2017, 9:34. doi:  10.1186/s13073-017-0424-2
    [41] Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348:124-128. doi:  10.1126/science.aaa1348
    [42] Sileni VC, Pigozzo J, Ascierto PA, et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme[J]. J Exp Clin Cancer Res, 2014, 33:30. doi:  10.1186/1756-9966-33-30
    [43] Leroy V, Gerard E, Dutriaux C, et al. Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma[J]. Cancer Immunol Immunother, 2019, 68:545-551. doi:  10.1007/s00262-019-02298-9
    [44] Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation[J]. N Engl J Med, 2015, 372:320-330. doi:  10.1056/NEJMoa1412082
    [45] Kugel CH, Douglass SM, Webster MR, et al. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations[J]. Clin Cancer Res, 2018, 24:5347-5356. doi:  10.1158/1078-0432.CCR-18-1116
    [46] Nosrati A, Tsai KK, Goldinger SM, et al. Evaluation of clinicopathological factors in PD-1 response:derivation and validation of a prediction scale for response to PD-1 monotherapy[J]. Br J Cancer, 2017, 116:1141-1147. doi:  10.1038/bjc.2017.70
    [47] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373:1627-1639. doi:  10.1056/NEJMoa1507643
    [48] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373:123-135. doi:  10.1056/NEJMoa1504627
    [49] Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 379:2040-2051. doi:  10.1056/NEJMoa1810865
    [50] Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 378:2078-2092. doi:  10.1056/NEJMoa1801005
    [51] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J]. Lancet, 2016, 387:1540-1550. doi:  10.1016/S0140-6736(15)01281-7
    [52] Nishijima TF, Muss HB, Shachar SS, et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients:A systematic review and meta-analysis[J]. Cancer Treat Rev, 2016, 45:30-37. doi:  10.1016/j.ctrv.2016.02.006
    [53] Elias R, Giobbie-Hurder A, McCleary NJ, et al. Efficacy of PD-1& PD-L1 inhibitors in older adults:a meta-analysis[J]. J Immunother Cancer, 2018, 6:26. doi:  10.1186/s40425-018-0336-8
    [54] Wu Q, Wang Q, Tang X, et al. Correlation between patients' age and cancer immunotherapy efficacy[J]. Oncoimmunology, 2019, 8:e1568810. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1080/2162402X.2019.1568810
    [55] Herin H, Aspeslagh S, Castanon E, et al. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours[J]. Eur J Cancer, 2018, 95:68-74. doi:  10.1016/j.ejca.2018.03.002
    [56] Dudnik E, Moskovitz M, Daher S, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer:The real-life data[J]. Lung Cancer, 2018, 126:217-223. doi:  10.1016/j.lungcan.2017.11.015
    [57] Muchnik E, Loh KP, Strawderman M, et al. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer[J]. J Am Geriatr Soc, 2019, 67:905-912. doi:  10.1111/jgs.15750
    [58] Lichtenstein MRL, Nipp RD, Muzikansky A, et al. Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC)[J]. J Thorac Oncol, 2019, 14:547-552. doi:  10.1016/j.jtho.2018.11.011
    [59] Sattar J, Kartolo A, Hopman WM, et al. The Efficacy and Toxicity of Immune Checkpoint Inhibitors in A Real-World Older Patient Population[J]. J Geriatr Oncol, 2019, 10:411-414. doi:  10.1016/j.jgo.2018.07.015
    [60] de Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients[J]. Cancer Immunol Res, 2017, 5:312-318. doi:  10.1158/2326-6066.CIR-16-0237
    [61] Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade[J]. N Engl J Med, 2018, 378:158-168. doi:  10.1056/NEJMra1703481
    [62] Leins H, Mulaw M, Eiwen K, et al. Aged murine hematopoietic stem cells drive aging-associated immune remodeling[J]. Blood, 2018, 132:565-576. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b2843c420e2791a3ccf06d34c11a7f93
    [63] Pawelec G. Immunosenescence and cancer[J]. Biogerontology, 2017, 18:717-721. doi:  10.1007/s10522-017-9682-z
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (559) PDF downloads(93) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return